Search results
Results From The WOW.Com Content Network
Shares of Viatris (NASDAQ: VTRS) were jumping 6% higher as of 11:18 a.m. ET on Thursday after rising as much as 12.4% earlier in the day. The solid gain came after the global healthcare company ...
AT&T (NYSE: T) has emerged as a standout performer in this environment, delivering a remarkable 41.5% year-to-date gain (as of Dec. 3, 2024), substantially outpacing the S&P 500's 26.8% rise so ...
The stock for both Realty and AT&T slumped in 2023 as rising interest rates drove investors toward risk-free CDs and T-bills instead of dividend stocks. But in 2024, both stocks warmed up again as ...
In 1976 the stock moved to the National Association of Securities Dealers Automated Quotations . Their final stock move was in 1986, when their stock became available for trade on the New York Stock Exchange under the ticker symbol MYL. Prior to the Viatris combination, the stock was traded on the NASDAQ.
Viatris stock trades at a forward price-to-earnings (P/E) ratio of just 4.33, well below the industry average of 17. ... Viatris offers shareholders a hefty 4.12% dividend yield. The downside is ...
Until recently, Viatris (NASDAQ:VTRS) was considered a value play among drug stocks. But after its recent earnings report, and announced sale of a key asset? The generic drug maker has been deemed ...
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn , a legacy division of Pfizer , on November 16, 2020.
The stock of Viatris (NAS:VTRS, 30-year Financials) is believed to be modestly undervalued, according to GuruFocus Value calculation.